Remember meForgot password?
    Log in with Twitter
Press Release

Xarelto Lawsuit Update: Increasing Number of Cases Filed in Phila. Mass Tort Group reports today with the updated number of cases in the Philadelphia mass tort Xarelto litigation.  The mass tort group in Philadelphia was formed after a motion was made to consolidate the rising number of cases in the area with similar allegations against the same defendants, the manufacturers of the blood thinner Xarelto, Bayer AG and Janssen Pharmaceuticals.

There are currently 430 cases filed in the mass tort group and this number is expected to rise as litigation continues.  Currently, the litigation is only in the pretrial stages and the trials are not expected to start for quite some time.  We will post updates on the Xarelto litigation on our website here as we receive them.

Lawsuits Allege Xarelto is Dangerous:

The lawsuits are able to be consolidated into a mass tort group because they all make similar allegations against the same defendants.  These lawsuits all similarly allege that Xarelto causes severe internal bleeding which can lead to serious injury or death in patients using the drug, that the manufacturers of Xarelto failed to adequately warn patients and doctors about the real dangers of the drug, and that the manufacturers of the drug were reckless in releasing the product to market without an antidote.  A full list of the lawsuits filed can be found here.

Xarelto’s Alleged Design Defect:

Xarelto is a part of a new class of blood thinners called Xa inhibitors.  Xa inhibitors work differently from the traditional blood thinners on the market because they prevent clots by blocking the agent in blood that makes it clot, thrombin.  By blocking thrombin, Xarelto completely takes away the blood’s ability to clot.  This is very dangerous considering the drug does not have an antidote to its anticoagulant effects.  This means that if a patient suffers from an internal bleeding injury there is no way to stop the bleeding short of extreme life saving medical interventions.  This is very different from the situation that patients are in if they are taking the drug Warfarin, a historically successful blood thinner.  If a patient experiences an internal bleeding injury while taking Warfarin, a doctor can administer Vitamin K, the effects of Warfarin will be reversed, and the blood will clot again.  Since Xarelto’s release, the FDA has issued several warnings regarding the safety of the drug and the drug has two ‘black box’ warnings attached to it.  The black box warning is the most strict warning the FDA can attach to the drug short of recalling it and it usually means that there is a reasonable risk of harm associated with usage of the drug.

“If you believe that you or a loved one have been harmed by Xarelto usage, contact us immediately.” Xarelto attorney Marc Goldich said, “Cases against the drug’s manufactures are being filed all across the country, yours could be next.”

For any questions regarding this press release or the pending Xarelto litigation, please contact Marc Goldich at (866) 425-8902.



Marc Goldich
1500 Walnut Street, 4th Floor, Philadelphia, PA 19102.

Latest News
Top News